Sysmex

The alliance follows a marketing deal signed with Sysmex Europe that covers Europe, the Middle East, and Africa.

The two companies plan to secure required initial regulatory approvals in individual African territories before expanding to other areas in the region.

The companies formed the joint venture in 2008 to commercialize BioMérieux's IVD products and medical instruments in Japan.

The acquisition allows Sysmex to enter the cytogenetics market and strengthens its technology base in molecular genetics, while expanding its life science business. 

The firms will set up sites for OncoBEAM RAS CRC in Argentina, Brazil, Malaysia, Indonesia, Vietnam, and India, and present data at major medical conferences.

The firms now plan to market the test in Europe, Asia, and Australia as a tool oncologists can use to identify best responders to EGFR inhibitors.

The partners will utilize Clearbridge's microfluidics-based rare cell separation technology, with the goal of potentially creating a new product line.

The agreement allows Sysmex to distribute two Streck blood collection tubes for cell-free DNA as part of its medical diagnostics products and services.

The companies said they aim to discover next-generation tests that will enable early diagnosis of dementia, as well as treatment selection and monitoring.

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.